期刊文献+

海捷亚治疗原发性高血压的临床观察 被引量:5

Effects of HYZAAR on Treatment of Essential Hypertension
暂未订购
导出
摘要 目的:观察海捷亚(氯沙坦钾/氢氯噻嗪片)对原发性高血压患者的降压疗效及不良反应。方法:为自身对照方式的多中心研究。选择490例Ⅰ、Ⅱ级原发性高血压病例,服海捷亚(每天晨服一次)共4周,观察用该药期间血压、心率及不良反应情况。结果:服海捷亚1周起,收缩压、舒张压、平均动脉压均显著下降(P<0.01),至第4周降压幅度最显著(P<0.001)。海捷亚对老年高血压与较年轻高血压患者同样有效。结论:海捷亚能有效控制血压,不良反应少。 To observe antihypertensive effect of HYZAAR (losastan potessium/hy-drochlerothiazide) in essential hypertension patients. Methods: This was a multicenter and follow-up study, 490 patients with mild-to-moderate hypertension were received HYZAAR 1 tablet per day for 4 weeks. Blood pressure, heart rate were measured. Side effects were observed. Results: SBP, DBP and MAP were significantly reduced at the first week (P<0.01) and the reduction at the forth week was the most remarkable (P < 0.001). HYZAAR was an effective drug for both elderly and younger patients. Conclusions: HYZAAR is an effective and safe agent in treatmen of Essential hypertension.
出处 《国外医学(心血管疾病分册)》 2002年第5期300-301,311,共3页
关键词 临床观察 海捷亚 氯沙坦钾 氢氯噻嗪 原发性高血压 降压药 HYZAAR Losartan Hydrochlocothiazide Essential hypertension
  • 相关文献

参考文献3

  • 1Anonymous. 1999 World Health Organzation-Intenational society of hypertension guidelines for the mangement of hypertension. J Hypertens, 1999; 17(2): 151~183
  • 2Mackay JH, Arcnri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med, 1996; 156(3): 278~285
  • 3Goldberg AI, Dunlay MC, Sweet CS, et al. Safety and tolerability of losartan potassium, an angiotensin Ⅱ receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol, 1995; 75(12): 793~795

同被引文献93

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部